Spero Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 46
- Market Cap
- $74.5M
- Introduction
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. M...
A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite (SPR1349) in Healthy Participants
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 46
- Registration Number
- NCT06727136
- Locations
- 🇺🇸
Medical Facility, Salt Lake City, Salt Lake City, Utah, United States
A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
- Conditions
- Interventions
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 2648
- Registration Number
- NCT06059846
- Locations
- 🇿🇦
Medical facility, Durban, South Africa
🇹🇷Medical Facility, Samsun, Turkey
A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT05966688
- Locations
- 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Oral Administration of Multiple Doses of SPR720 in Healthy Volunteers.
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 33
- Registration Number
- NCT05955586
- Locations
- 🇺🇸
Pulmonary Associates, Phoenix, Arizona, United States
A Study to Compare Two Bioanalytical Assays for Tebipenem
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT05856747
- Locations
- 🇺🇸
BioPharma Services, Creve Coeur, Missouri, United States
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 25
- Registration Number
- NCT05496374
- Locations
- 🇺🇸
Medical Facility, Tyler, Texas, United States
🇺🇸Medical facility, Atlanta, Georgia, United States
Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 34
- Registration Number
- NCT04868292
- Locations
- 🇬🇧
Medical Facility, Manchester, United Kingdom
Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 37
- Registration Number
- NCT04865393
- Locations
- 🇳🇿
Medical Facility, Christchurch, New Zealand
Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking Volunteers
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT04710407
- Locations
- 🇺🇸
Pulmonary Associates, Phoenix, Arizona, United States
Study of the Absorption, Metabolism, and Excretion of [14C]-Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) Following a Single Oral Dose in Healthy Male Subjects
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 8
- Registration Number
- NCT04625855
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States